mRNA vaccines went from research curiosity to global infrastructure during the COVID-19 pandemic. The platform’s flexibility — change the antigen, keep everything else the same — has implications well beyond infectious disease.
The basic mechanism
Traditional vaccines deliver an antigen (a protein, attenuated virus, or inactivated pathogen) directly. mRNA vaccines deliver instructions for the body to make the antigen itself. The steps:
- mRNA encoding the target antigen is delivered into cells, packaged in a lipid nanoparticle (LNP)
- The cell’s ribosomes translate the mRNA into protein
- The translated protein is processed and presented on MHC class I (intracellular) or secreted/displayed and engulfed by antigen-presenting cells (MHC class II)
- Both arms of the adaptive immune system — antibody and T-cell — respond
- Memory B and T cells provide long-term immunity
Why mRNA had to be engineered
Native mRNA triggers strong innate immune responses (via TLR7, TLR8, RIG-I) and is rapidly degraded by RNases. Several engineering tricks make therapeutic mRNA viable:
- Pseudouridine substitution: Replacing uridine with pseudouridine or N1-methylpseudouridine reduces innate immune activation and improves translation
- 5′ cap structure: Cap1 (m7GpppNm) mimics endogenous mRNA and improves stability
- Optimized UTRs: 5′ and 3′ untranslated regions chosen for high translational efficiency
- Codon optimization: Replace rare codons with more abundant ones to improve translation rate
- Poly(A) tail: Long, well-defined poly(A) tail (~120 nt) for stability
Lipid nanoparticles (LNPs)
The other half of the platform. LNPs are typically composed of four lipids:
- Ionizable lipid: Charged at low pH (encapsulates mRNA), neutral at physiological pH (low toxicity)
- Phospholipid: Structural component (e.g., DSPC)
- Cholesterol: Membrane stability
- PEGylated lipid: Surface protection, prevents aggregation
Mixed in microfluidic devices, LNPs encapsulate mRNA with high efficiency and deliver it intracellularly via endocytosis. Once inside the endosome, the ionizable lipid becomes positively charged at low pH, destabilizes the endosome, and releases mRNA into the cytoplasm.
Manufacturing workflow
- Plasmid DNA template encoding the antigen + regulatory elements
- In vitro transcription using T7 RNA polymerase (with modified nucleotides)
- Capping reaction (or co-transcriptional capping)
- Purification: DNase digestion, chromatography, tangential flow filtration
- QC: identity (sequencing), integrity (capillary electrophoresis), endotoxin testing
- LNP formulation: microfluidic mixing, buffer exchange, sterile filtration
- Final fill-finish into vials
Why mRNA changed vaccinology
- Speed: A new sequence can be designed and produced in weeks, not years
- Modularity: Same manufacturing platform for any antigen
- No live pathogens or cell culture: Cell-free, fully synthetic
- Strong T-cell response: Comparable to viral vector vaccines
- Multivalency: Multiple antigens can be co-formulated easily
Applications beyond COVID-19
- Influenza, RSV, CMV, HIV, malaria, tuberculosis vaccines in clinical trials
- Cancer immunotherapy: personalized neoantigen vaccines tailored to a patient’s tumor mutations
- Protein replacement therapies (delivering mRNA encoding missing or defective proteins)
- Gene editing delivery (Cas9 mRNA + sgRNA in LNPs)
Limitations and active research areas
- Cold chain requirements: Most mRNA vaccines require -20 to -70 °C storage
- Reactogenicity: Local and systemic side effects related to LNP and innate immune activation
- Tropism: Most LNPs go to liver after IV injection; intramuscular delivery localizes to muscle and draining lymph nodes
- Self-amplifying mRNA (saRNA): Encodes a viral replicase that amplifies the mRNA in the cell, allowing lower doses
The mRNA platform is now a permanent fixture in vaccine and therapeutic development. Whatever the next outbreak or rare disease, the same manufacturing infrastructure can pivot in weeks.
